ACE-inhibitor ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
218Alport syndrome2

218. Alport syndrome


Clinical trials : 30 Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00309257
(ClinicalTrials.gov)
January 200430/3/2006Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeEffects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeAlport SyndromeDrug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and FluvastatinMario Negri Institute for Pharmacological ResearchNULLCompleted15 Years70 YearsBoth9Phase 2Italy
2NCT02378805
(ClinicalTrials.gov)
July 199526/2/2015European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeEuropean Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel TherapiesFamilial Benign Hematuria;Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane DiseaseDrug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol;Drug: SGLT2 inhibitorUniversity Hospital GoettingenSociety for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive MedicineRecruitingN/AN/AAll500Germany